Reverse Payments by Drug Companies: The Supreme Court Declines to Adopt a Bright-Line Test (PDF)

The Federal Trade Commission has long opposed "reverse payments," the practice by which a pioneer drug company selling a brand-name drug pays a generic drug company to not enter the market.

Publisher :LexisNexis Emerging Issues Analysis
Format: Electronic, 3 Pages , PDF

ISBN: 9781422429983

Less More

Shop eBooks Place International Order